PD-L1 co-stimulation, ligand-induced TCR down-modulation and anti-tumor immunotherapy.
PD-1 engagement on the surface of effector T cells strongly suppresses their cytotoxic function, which constitutes a major obstacle for T cell-mediated anti-tumor activities. Surprisingly, PD-1 is strongly upregulated in T cells, engaging its ligand PD-L1 during antigen presentation. However, our recent published data may provide an explanation for this apparent contradiction.
Center for Neurologic Disease; Harvard Medical School; Boston, MA USA.
Katarzyna
K
Karwacz
Frederick
F
Arce
Christopher
C
Bricogne
Grazyna
G
Kochan
David
D
Escors